Share This

Hot News

Omicron|專治輕型普通型首個國產特效藥實驗表現出良好活性 @ 2021-12-11T16: Back Hot News
Keyword:新冠 批准
Concept:批准大陸首款新冠特效藥 , 中國首個新冠病毒中和抗體聯合
香港大學工程團隊研發了一款高銅含量的不銹鋼,能在3小時內殺死99.75%的新冠病毒,目前已在申請專利,期望能廣泛應用在一些公共場所,比方電梯按鈕等。另外,大陸8號也批准首個新冠特效藥緊急使用,透過「安巴韋」及「羅米思韋」2款單抗注射液,混和使用,這特效藥,能讓新冠患者住院及死亡率降低80%。新藥助力抗疫,現在大陸的本土疫情仍舊止不住,更有向南方延伸趨勢,浙江杭州、寧波和紹興截止9號,確診加無症狀感染累計已有59例。
大陸國家藥品監督管理局8日晚間發布消息,宣布應急批准騰盛華創醫藥技術(北京)有限公司新冠病毒中和抗體聯合治療藥物安巴韋單抗注射液(BRII-196)及羅米司韋單抗注射液(BRII-198)注冊申請。這是大陸首家獲批的自主知識產權新冠病毒中和抗體聯合治療藥物。
距離北京冬奧只剩56天,但大陸北方疫情持續吃緊,大陸8日新增本土病例有60例,包括疫情持續延燒的內蒙古再增42例。不過,在新冠藥物研究上,大陸出現新突破,大陸國家藥監局日前公布,已應急批准大陸首款新冠特效藥,據稱,此款中和抗體療法將可降低78%的住院和死亡率。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.